171 related articles for article (PubMed ID: 9649923)
1. Pathogenetic implications of hyaluronan-induced modification of vascular smooth muscle cell fibrinolysis in diabetes.
Marutsuka K; Woodcock-Mitchell J; Sakamoto T; Sobel BE; Fujii S
Coron Artery Dis; 1998; 9(4):177-84. PubMed ID: 9649923
[TBL] [Abstract][Full Text] [Related]
2. T-cell lymphokines, interleukin-4 and gamma interferon, modulate the induction of vascular smooth muscle cell tissue plasminogen activator and migration by serum and platelet-derived growth factor.
Wang W; Chen HJ; Giedd KN; Schwartz A; Cannon PJ; Rabbani LE
Circ Res; 1995 Dec; 77(6):1095-106. PubMed ID: 7586221
[TBL] [Abstract][Full Text] [Related]
3. Antifibrinolytic properties of the vascular wall. Dependence on the history of smooth muscle cell doublings in vitro and in vivo.
Christ G; Hufnagl P; Kaun C; Mundigler G; Laufer G; Huber K; Wojta J; Binder BR
Arterioscler Thromb Vasc Biol; 1997 Apr; 17(4):723-30. PubMed ID: 9108786
[TBL] [Abstract][Full Text] [Related]
4. Glucose and insulin independently reduce the fibrinolytic potential of human vascular smooth muscle cells in culture.
Pandolfi A; Iacoviello L; Capani F; Vitacolonna E; Donati MB; Consoli A
Diabetologia; 1996 Dec; 39(12):1425-31. PubMed ID: 8960822
[TBL] [Abstract][Full Text] [Related]
5. The inflammatory cytokine oncostatin M induces PAI-1 in human vascular smooth muscle cells in vitro via PI 3-kinase and ERK1/2-dependent pathways.
Demyanets S; Kaun C; Rychli K; Rega G; Pfaffenberger S; Afonyushkin T; Bochkov VN; Maurer G; Huber K; Wojta J
Am J Physiol Heart Circ Physiol; 2007 Sep; 293(3):H1962-8. PubMed ID: 17604327
[TBL] [Abstract][Full Text] [Related]
6. Effects of black cohosh on the plasminogen activator system in vascular smooth muscle cells.
Lee DY; Roh CR; Kang YH; Choi D; Lee Y; Rhyu MR; Yoon BK
Maturitas; 2013 Sep; 76(1):75-80. PubMed ID: 23827472
[TBL] [Abstract][Full Text] [Related]
7. Effects of thrombin on steroid-modulated cultured endometrial stromal cell fibrinolytic potential.
Lockwood CJ; Krikun G; Aigner S; Schatz F
J Clin Endocrinol Metab; 1996 Jan; 81(1):107-12. PubMed ID: 8550736
[TBL] [Abstract][Full Text] [Related]
8. T cell lymphokines modulate bFGF-induced smooth muscle cell fibrinolysis and migration.
Wang W; Chen HJ; Schwartz A; Cannon PJ; Rabbani LE
Am J Physiol; 1997 Feb; 272(2 Pt 1):C392-8. PubMed ID: 9124280
[TBL] [Abstract][Full Text] [Related]
9. Retroviral vector-mediated transfer and expression of human tissue plasminogen activator gene in human endothelial and vascular smooth muscle cells.
Ekhterae D; Stanley JC
J Vasc Surg; 1995 Jun; 21(6):953-62. PubMed ID: 7776475
[TBL] [Abstract][Full Text] [Related]
10. Plasminogen activator and plasminogen activator inhibitor expression by normal and aneurysmal human aortic smooth muscle cells in culture.
Louwrens HD; Kwaan HC; Pearce WH; Yao JS; Verrusio E
Eur J Vasc Endovasc Surg; 1995 Oct; 10(3):289-93. PubMed ID: 7552526
[TBL] [Abstract][Full Text] [Related]
11. Modulation of tissue-type plasminogen activator expression by platelet activating factor in human glioma cells.
Akai T; Niiya K; Sakuragawa N; Iizuka H; Endo S
J Neurooncol; 2002 Sep; 59(3):193-8. PubMed ID: 12241114
[TBL] [Abstract][Full Text] [Related]
12. Expression of the plasminogen activator system in the human vascular wall.
Salame MY; Samani NJ; Masood I; deBono DP
Atherosclerosis; 2000 Sep; 152(1):19-28. PubMed ID: 10996335
[TBL] [Abstract][Full Text] [Related]
13. Combined effect of retinoic acid and basic FGF on PAI-1 gene expression in vascular smooth muscle cells.
Watanabe A; Kurabayashi M; Arai M; Sekiguchi K; Nagai R
Cardiovasc Res; 2001 Jul; 51(1):151-9. PubMed ID: 11399257
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin II increases plasminogen activator inhibitor type 1 and tissue-type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells.
van Leeuwen RT; Kol A; Andreotti F; Kluft C; Maseri A; Sperti G
Circulation; 1994 Jul; 90(1):362-8. PubMed ID: 8026020
[TBL] [Abstract][Full Text] [Related]
15. Sodium hyaluronate increases the fibrinolytic response of human peritoneal mesothelial cells exposed to tumor necrosis factor alpha.
Reijnen MM; van Goor H; Falk P; Hedgren M; Holmdahl L
Arch Surg; 2001 Mar; 136(3):291-6. PubMed ID: 11231848
[TBL] [Abstract][Full Text] [Related]
16. Biological mechanisms underlying the clinical effects of RU 486: modulation of cultured endometrial stromal cell plasminogen activator and plasminogen activator inhibitor expression.
Lockwood CJ; Krikun G; Papp C; Aigner S; Schatz F
J Clin Endocrinol Metab; 1995 Apr; 80(4):1100-5. PubMed ID: 7714076
[TBL] [Abstract][Full Text] [Related]
17. Effects of cadmium on the release of tissue plasminogen activator and plasminogen activator inhibitor type 1 from cultured human vascular smooth muscle cells and fibroblasts.
Yamamoto C; Kaji T; Sakamoto M; Kozuka H
Toxicology; 1996 Jan; 106(1-3):179-85. PubMed ID: 8571389
[TBL] [Abstract][Full Text] [Related]
18. Contrasting effects of plasminogen activators, urokinase receptor, and LDL receptor-related protein on smooth muscle cell migration and invasion.
Okada SS; Grobmyer SR; Barnathan ES
Arterioscler Thromb Vasc Biol; 1996 Oct; 16(10):1269-76. PubMed ID: 8857924
[TBL] [Abstract][Full Text] [Related]
19. Plasminogen activator activity during decidualization of human endometrial stromal cells is regulated by plasminogen activator inhibitor 1.
Schatz F; Aigner S; Papp C; Toth-Pal E; Hausknecht V; Lockwood CJ
J Clin Endocrinol Metab; 1995 Aug; 80(8):2504-10. PubMed ID: 7629251
[TBL] [Abstract][Full Text] [Related]
20. Stimulation of PAI-1 expression in endothelial cells by cultured vascular smooth muscle cells.
Gallicchio M; Argyriou S; Ianches G; Filonzi EL; Zoellner H; Hamilton JA; McGrath K; Wojta J
Arterioscler Thromb; 1994 May; 14(5):815-23. PubMed ID: 8172858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
